Gefitinib (ZD1839) is a potent, selective, and orally active EGFR tyrosine kinase inhibitor that inhibits EGF-stimulated tumor cell growth by blocking EGF-induced EGFR autophosphorylation in tumor cells. Here, EGFR is linked to neoplasm.